Health System Renewals: The ROI Beyond Clinical Efficacy

The Imperative of Quantifiable Value: Beyond Clinical Efficacy

For health system buyers, the decision to renew or expand a digital health contract transcends mere clinical success. While improved patient outcomes are foundational, they must be inextricably linked to tangible economic benefits or operational improvements. This is particularly true for solutions in competitive clusters like remote patient monitoring, where the market demands clear differentiation based on value. Companies must move beyond simply demonstrating efficacy in randomized controlled trials (RCTs) to proving their financial contribution within the complex ecosystem of enterprise healthcare. Consider the case of hospital-at-home programs, a strategic initiative for many health systems, including Kaiser Permanente. These programs aim to shift acute care from inpatient facilities to patients’ homes, promising significant cost reductions and improved patient experience. Platforms like Biofourmis, which partners with health systems for hospital-at-home initiatives, understand this dynamic. Their success in securing and renewing contracts is predicated on their ability to document not only reductions in readmission rates or lengths of stay, but also the direct financial savings realized by the health system. For example, in a study with Brigham and Women’s Hospital, home-based patients experienced 70% lower readmissions over 30 days and a 38% reduction in care costs compared to usual hospital care. This involves precise measurement of avoided inpatient days, reduced resource utilization, and improved patient flow. Biofourmis hospital-at-home economic impact study

Documenting Clinical Outcomes to Justify Enterprise Pricing

The first layer of justification for enterprise pricing is, undeniably, strong clinical outcomes. These outcomes must be published in peer-reviewed journals, providing an authoritative and objective validation of the platform’s efficacy. For instance, Propeller Health, a digital therapeutic providing respiratory care, has consistently documented its impact on asthma and COPD management. Their published studies often highlight:

• Reduction in emergency department visits and hospitalizations: Propeller Health has demonstrated reductions in asthma-related ED visits and hospitalizations by up to 57%, and COPD-related ED visits and hospitalizations by up to 35%. This is a direct clinical benefit that translates into significant cost savings for risk-bearing entities.
• Improved medication adherence: Propeller Health has shown an increase in medication adherence by up to 58%. This leads to better disease control and reduced exacerbations.
• Enhanced quality of life metrics: While harder to quantify financially, these contribute to patient satisfaction and overall system reputation. Such evidence provides the foundational “why” for adoption. However, for a solution to move from a pilot to a full-scale deployment, this clinical success must be interwoven with an economic narrative. It is not enough to show that patients are healthier. The platform must demonstrate how it helps the health system achieve its financial and operational goals. This requires a deep understanding of health system economics, including DRG payments, readmission penalties, and resource allocation.
  

  Operational ROI: The Unsung Hero of Renewals

  Beyond clinical outcomes, the operational return on investment often dictates the longevity of a digital health contract. This encompasses how a platform simplifies workflows, reduces administrative burden, and optimizes existing resources. For health systems, particularly large integrated delivery networks like Kaiser Permanente, efficiency gains can be as impactful as direct cost savings.

• Staffing optimization: Can the platform reduce the need for certain types of staff, or reallocate existing staff to higher-value tasks? For RPM solutions, this might involve intelligent alert systems that minimize false alarms, allowing nurses to focus on critical cases.
• Reduced administrative overhead: Automated data collection and reporting can significantly cut down on manual tasks, freeing up valuable personnel time.
• Improved patient engagement and retention: While seemingly qualitative, higher patient engagement can lead to better adherence to care plans, reducing downstream costs and improving population health metrics, which are critical for value-based care models. The challenge for digital health companies is to move beyond anecdotal evidence of these operational benefits. They must embed automated data-collection mechanisms within their platforms to continuously prove economic value. This means tracking metrics like nurse time saved per patient, reduction in call center volume, or percentage decrease in no-show appointments. These data points, when aggregated and presented clearly, form a powerful case for renewal. Journal of Medical Internet Research article on digital health ROI
  

  The Necessity of Continuous, Automated Data Collection

  Startups in the digital health space often excel at clinical innovation but sometimes falter in embedding the necessary mechanisms for continuous economic validation. To secure enterprise renewals, platforms must be designed from the ground up to automatically collect and report on both clinical and operational key performance indicators (KPIs). This isn’t merely about generating a quarterly report. It’s about providing real-time, transparent data that health system buyers can use to justify their investment to internal stakeholders. This includes:

• Integration with existing EHR systems: Smooth data flow is important for demonstrating impact without adding to staff burden.
• Customizable dashboards: Health systems need to see the data that matters most to their specific strategic priorities, whether it’s reducing 30-day readmissions or improving chronic disease management metrics.
• Benchmarking capabilities: The ability to compare a health system’s performance against anonymized peer data or industry benchmarks can further highlight the value proposition. Without these embedded data-collection and reporting capabilities, even the most clinically effective digital health solution risks becoming a “zombie company”, one that has achieved initial traction but struggles to scale due to an inability to continuously prove its economic worth. Investors conducting due diligence on such companies will scrutinize their QMS / ISO 13485 compliance and their ability to generate real-world evidence (RWE) that goes beyond initial pilot data. Health Affairs article on digital health adoption challenges
  

  Methodology and Source Note

  This analysis is grounded in a thorough review of published peer-reviewed outcomes data, health system pilot reports, and economic studies focusing on remote patient monitoring and hospital-at-home models. Specific examples from Biofourmis and Propeller Health are drawn from their publicly available clinical and economic impact reports, often published in journals like Nature Medicine or JMIR, and press releases detailing partnerships with major health systems such as Kaiser Permanente. The quantitative benchmarks and qualitative rules of thumb presented reflect common themes identified across successful enterprise-level digital health deployments and renewals. The insights herein are designed to serve as an investment thesis and roadmap for digital health founders and health system CFOs, emphasizing the critical interplay between clinical efficacy and demonstrable economic value.